Share on StockTwits
 

Equities Research Analysts’ ratings reiterations for Monday, January 27th:

Altera Corp. (NASDAQ:ALTR) had its neutral rating reiterated by analysts at Zacks. The firm currently has a $34.00 price target on the stock. Zacks’ analyst wrote, “Altera delivered encouraging fourth-quarter 2013 results with both earnings and revenues beating the Zacks Consensus Estimate. Although revenues increased year over year, earnings dropped sharply due to higher operating expenses. Guidance for the upcoming quarter was also tepid. Nonetheless, China LTE shipments are expected to aid wireless revenues and more than offset a decline in telecom revenues. However, macroeconomic weakness, competition from Xilinx Inc. and Lattice Semiconductor Corp., consolidation in the telecom market, declining margins and volatility in the semiconductor market are concerns. Thus, we reiterate our Neutral recommendation on Altera and set a target price of $34.00.”

Applied Micro Circuits Corp. (NASDAQ:AMCC) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $12.00 target price on the stock. Zacks’ analyst wrote, “Applied Micro reported modest third quarter fiscal 2014 results with a year-over-year increase in both revenues and adjusted earnings. We believe that Applied Micro is well positioned to grow its market share based on its diversified product offerings, such as X-Gene and X-Weave products. In addition, the company’s strong associations with renowned server OEMs are expected to augment its business going forward. However, the competitive strides in the industry are likely to have a detrimental impact on its businesses. Management is also concerned about the macroeconomic challenges. Nevertheless, we maintain our long-term Neutral recommendation for the stock. “

Avnet (NYSE:AVT) had its neutral rating reiterated by analysts at Zacks. The firm currently has a $44.00 target price on the stock. Zacks’ analyst wrote, “Avnet posted better-than-expected second-quarter fiscal 2014 results. However, the guidance was less-than-encouraging due to seasonality in the western regions and below-normal seasonality in the Asia region due to a possible slump in the high volume fulfillment business. Nonetheless, we look forward to management’s decision to optimize costs and investments to tap the changing demand. Avnet’s leading position in electronics distribution, continuous cost cutting initiatives and acquisition synergies are encouraging. However, competition for both its domestic and foreign operations, especially from archrival Arrow Electronics Inc. and sluggish macroeconomic concerns keep us on the sidelines.”

Bombardier (TSE:BBD.B) had its buy rating reiterated by analysts at Citigroup Inc.. The firm currently has a C$5.00 target price on the stock, down from their previous target price of C$6.00.

Bristol-Myers Squibb (NYSE:BMY) had its neutral rating reissued by analysts at Zacks. The firm currently has a $53.00 target price on the stock. Zacks’ analyst wrote, “Bristol-Myers’ fourth quarter 2013 adjusted earnings of $0.51 per share beat the Zacks Consensus Estimate by $0.09. Adjusted earnings were 9% above the year-ago figure driven by higher revenues and lower costs. Net sales in the reported quarter increased 6% to $4.4 billion, driven by strong sales of cancer drugs. Revenues edged past the Zacks Consensus Estimate of $4.3 billion. Bristol-Myers has been trying to offset the declining sales of some of its important products by bringing in new products through in-licensing deals. We are also impressed by the company’s efforts to develop its pipeline. We believe that the stock is fairly valued at current levels with limited scope for appreciation and hence retain our Neutral recommendation.”

Facebook (NASDAQ:FB) had its in-line rating reaffirmed by analysts at Cantor Fitzgerald.

Hexcel Corp. (NYSE:HXL) had its buy rating reissued by analysts at Canaccord Genuity.

International Business Machines Corp. (NYSE:IBM) had its buy rating reiterated by analysts at TheStreet. The analysts wrote, “International Business Machines (IBM) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company’s strengths can be seen in multiple areas, such as its growth in earnings per share, good cash flow from operations, increase in net income and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.”

International Business Machines Corp. (NYSE:IBM) had its neutral rating reissued by analysts at Zacks. The firm currently has a $189.00 price target on the stock.

Intel Corp. (NASDAQ:INTC) had its buy rating reaffirmed by analysts at TheStreet. The analysts wrote, “Intel (INTC) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company’s strengths can be seen in multiple areas, such as its increase in stock price during the past year, revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.”

LinkedIn Corp. (NYSE:LNKD) had its sell rating reiterated by analysts at TheStreet. The analysts wrote, “LinkedIn (LNKD) has been reiterated by TheStreet Ratings as a sell with a ratings score of D+. The company’s weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and disappointing return on equity.”

Mothercare (LON:MTC) had its sell rating reissued by analysts at Cantor Fitzgerald Europe. The firm currently has a GBX 200 ($3.30) price target on the stock.

Mothercare (LON:MTC) had its sell rating reaffirmed by analysts at Cantor Fitzgerald Europe. They currently have a GBX 200 ($3.30) target price on the stock.

Mothercare (LON:MTC) had its sell rating reissued by analysts at Cantor Fitzgerald Europe. Cantor Fitzgerald Europe currently has a GBX 200 ($3.30) price target on the stock.

Mothercare (LON:MTC) had its sell rating reaffirmed by analysts at Cantor Fitzgerald Europe. The firm currently has a GBX 200 ($3.30) target price on the stock.

Mothercare (LON:MTC) had its sell rating reissued by analysts at Cantor Fitzgerald Europe. Cantor Fitzgerald Europe currently has a GBX 200 ($3.30) price target on the stock.

Mothercare (LON:MTC) had its sell rating reaffirmed by analysts at Cantor Fitzgerald Europe. The firm currently has a GBX 200 ($3.30) target price on the stock.

Maxim Integrated Products (NASDAQ:MXIM) had its underperform rating reissued by analysts at Zacks. Zacks currently has a $27.00 target price on the stock. Zacks’ analyst wrote, “Maxim is an OEM of analog and mixed signal ICs. December quarter earnings beat the Zacks Consensus Estimate. Maxim’s strong business model coupled with strong profitability allows it to return a significant portion of free cash flow to shareholders. Maxim’s mobile strategy is likely to help its growth prospects over the next few years. Though Maxim’s product line and pipeline remain solid and its end-market diversity commendable, we believe its exposure to the consumer and computing markets increases risks. Also, customer concentration and increased volatility in results may be expected. Considering these factors we have an Underperform recommendation on Maxim shares.”

Pharmacyclics (NASDAQ:PCYC) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $142.00 target price on the stock. Zacks’ analyst wrote, “The approval of Imbruvica for treating MCL patients in Nov 2013 is a positive for Pharmacyclics. However, Imbruvica’s commercial potential for MCL is limited, given the small target population. We expect approval of the drug for the more lucrative CLL/SLL indication by Feb 28, 2014. Imbruvica is also being evaluated for other oncology indications by Pharmacyclics and partner Johnson & Johnson. We expect investor focus to remain on Imbruvica updates. We believe that the company must expand its pipeline to reduce dependence on Imbruvica. We are initiating coverage on the stock with a Neutral recommendation as the scope for appreciation from current levels appears limited until further visibility is obtained on Imbruvica’s initial sales. “

Procter & Gamble Co. (NYSE:PG) had its neutral rating reaffirmed by analysts at Zacks. They currently have a $83.00 price target on the stock. Zacks’ analyst wrote, “Despite worse-than-expected currency headwinds, P&G reported mixed fiscal second-quarter 2014 results beating the Zacks Consensus Estimate for earnings but missing the same for sales. Pricing improved in the quarter and margins were better than the previous quarter. The consumer products giant also maintained its financial outlook for fiscal 2014.Overall, we are encouraged by P&G’s strong brand recognition, diversified portfolio, rapid growth in developing nations, impressive product development capabilities and marketing prowess. The company’s improving market share trends, disciplined geographic/product expansion and accelerated cost savings bode well for further growth. Though weaker in the first half, earnings growth is expected to accelerate in the second half. However, currency headwinds, rising commodity costs, increasing competitive pressures, challenging consumer spending environment in the U.S. and volatile market dynamics in other countries remain overhangs. We would like to see significant margin improvement before becoming more positive on the stock.”

Quality Systems (NASDAQ:QSII) had its neutral rating reiterated by analysts at Zacks. The firm currently has a $19.00 target price on the stock. Zacks’ analyst wrote, “Despite the revenues and earnings miss from the Zacks Consensus Estimate in the third quarter of fiscal 2014, we are optimistic about Quality Systems given the continued strength in its NextGen division as well as the expected benefit from its Mirth acquisition. However, we are disappointed about the continued fall in software and hardware sales leading to lower revenues and earnings in the most recent quarter. Further, we are concerned about the company’s lack of endeavor to capitalize on opportunities in the growing EHR replacement market. Due to these mixed factors, we continue with our Neutral recommendation and set a target price of $19.00.”

Starbucks Corp. (NASDAQ:SBUX) had its neutral rating reiterated by analysts at Zacks. The firm currently has a $79.00 target price on the stock. Zacks’ analyst wrote, “Starbucks delivered mixed first-quarter fiscal 2014 results, beating the Zacks Consensus Estimate for earnings but missing the same for revenues as U.S. sales slowed. However, Starbucks raised earnings expectations for 2014 while maintaining the top-line guidance. Overall, we are encouraged by Starbucks’ strong global retail footprint, successful food/beverage innovations, rapid growth in international markets and solid turnaround in the U.S. We believe that the company has compelling growth drivers like La Boulange, Evolution Fresh, Teavana, K-Cups, loyalty program and food innovations to sustain the earnings momentum. However, macro challenges in Europe and the recent slowdown of the CPG business keeps us on the sidelines. “

Shaftesbury (LON:SHB) had its buy rating reaffirmed by analysts at Cantor Fitzgerald Europe. Cantor Fitzgerald Europe currently has a GBX 700 ($11.53) price target on the stock.

Shaftesbury (LON:SHB) had its buy rating reissued by analysts at Cantor Fitzgerald Europe. The firm currently has a GBX 700 ($11.53) target price on the stock.

Shaftesbury (LON:SHB) had its buy rating reaffirmed by analysts at Cantor Fitzgerald Europe. The firm currently has a GBX 700 ($11.53) target price on the stock.

Shaftesbury (LON:SHB) had its buy rating reaffirmed by analysts at Cantor Fitzgerald Europe. They currently have a GBX 700 ($11.53) target price on the stock.

Shaftesbury (LON:SHB) had its buy rating reaffirmed by analysts at Cantor Fitzgerald Europe. They currently have a GBX 700 ($11.53) price target on the stock.

Shaftesbury (LON:SHB) had its buy rating reiterated by analysts at Cantor Fitzgerald Europe. They currently have a GBX 700 ($11.53) target price on the stock.

Schlumberger (NYSE:SLB) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $93.00 target price on the stock. Zacks’ analyst wrote, “We are maintaining our Neutral recommendation on Schlumberger following its strong fourth-quarter results, which were aided by international exposure, solid execution and integration capabilities. Also contributing to the positive results were Schlumberger’s performances in the Gulf of Mexico region and its diverse product offerings. However, these factors were partially offset by seasonal activity slowdown, weather-related work delays and lower pricing due to excess capacity in the U.S. Also, Schlumberger faces a number of headwinds, including changes in exploration and production spending patterns, commodity price fluctuations and overall economic conditions. Given these factors, we expect shares of Schlumberger to perform in line with the broader equity market.”

Snap-On (NYSE:SNA) had its neutral rating reissued by analysts at Zacks. They currently have a $105.00 price target on the stock. Zacks’ analyst wrote, “We are reaffirming our Neutral recommendation on Snap-on Incorporated with a price target of $105. Third quarter 2013 earnings improved 13.5% year over year. Sales for the Snap-on Tools Group were up 8.1% in the reported quarter. The company witnessed growth across three of its four businesses during the quarter. The encouraging quarterly performance was primarily driven by the company’s ongoing strategic investments to strengthen its mobile tool distribution network, proliferation in the vehicle repair garage, expansion of critical industries and expansion in the emerging markets. The company’s recent acquisitions and increased sales in Original Equipment Manufacturer (OEM) business are also aiding the growth momentum. However, the prevailing uncertainty in U.S. government is proving to be a headwind for the company and is limiting the future visibility of the company.”

VF Corp. (NYSE:VFC) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $61.00 target price on the stock. Zacks’ analyst wrote, “We remain impressed with V.F. Corp.’s consistently positive earnings surprise trend, robust organic revenue growth and strong guidance. Moreover, we remain encouraged by the company’s recently completed stock split, which instills further momentum into the stock. We believe V.F. Corp’s initiatives to capitalize on opportunities in emerging markets and its focus on core business activities will lead to a better operating performance. The company’s growth prospects look promising, given its sustained focus on strategic acquisitions and the expansion of its global operations, which will boost its top and bottom lines. However, the prevalent soft macroeconomic environment, stiff competition and volatile raw material prices remain plausible concerns. Therefore, our long-term Neutral recommendation on the stock remains in place.”

Vodafone Group plc (LON:VOD) had its buy rating reiterated by analysts at Citigroup Inc..

Waste Management (NYSE:WM) had its neutral rating reiterated by analysts at Zacks. The firm currently has a $44.00 target price on the stock. Zacks’ analyst wrote, “Waste Management reported strong third quarter 2013 results with a year-over-year increase in both earnings and revenues. The company is continuing with its restructuring initiatives, which are likely to reap benefits in the long run. Waste Management is also taking adequate measures to improve its yield in the coming year and at the same time remains focused on controlling its costs. The company continues to return significant cash to its shareholders through dividends. However, high market price volatility, recycling operations headwinds, and huge integration costs related to acquisition could impair its long-term profitability to some extent. Nevertheless, we maintain our long-term Neutral recommendation for the stock”

Xilinx (NASDAQ:XLNX) had its neutral rating reiterated by analysts at Zacks. The firm currently has a $49.00 target price on the stock. Zacks’ analyst wrote, “Xilinx reported mixed third-quarter results wherein the bottom line beat the Zacks Consensus Estimate, while the top line fell short of the same. The fourth-quarter revenue guidance was tepid. Nonetheless, the growing demand for 28-nm nodes driven by higher wireless deployments and strength in the wired communication segment are expected to remain growth drivers. The company’s product launches are also expected to boost revenues in the forthcoming quarters. However, stiff competition from Altera and dwindling PC market sales keep us concerned for the near term. Thus, we reiterate our Neutral recommendation on Xilinx. “

Xerox Corp. (NYSE:XRX) had its neutral rating reissued by analysts at Zacks. They currently have a $12.00 price target on the stock. Zacks’ analyst wrote, “Xerox reported modest fourth quarter 2013 results as adjusted earnings of $0.29 per share matched with the Zacks Consensus Estimate. Moving forward, Xerox expects to realign its business model to better adapt to the evolving market trends by expanding indirect distribution channel and streamlining its supply chain. Xerox also intends to focus more on vertical markets like healthcare. In addition, it is integrating its Managed Print Services with business process and IT outsourcing capabilities to increase revenues from the Services segment to 66% of total revenue by 2017. However, the presence of a large number of substitutes and strong competition are likely to peg back its profitability to some extent. Nevertheless, we maintain our long-term Neutral recommendation for the stock. “

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.